Galectin Therapeutics Inc. (NASDAQ:GALT) shares traded up 5.9% during trading on Thursday . The company traded as high as $2.06 and last traded at $1.98, with a volume of 120,394 shares changing hands. The stock had previously closed at $1.87.

A number of research analysts recently commented on the stock. HC Wainwright reaffirmed a “buy” rating on shares of Galectin Therapeutics in a research report on Thursday, May 12th. FBR & Co reaffirmed a “buy” rating and issued a $12.00 target price on shares of Galectin Therapeutics in a research report on Thursday, August 11th. Zacks Investment Research downgraded shares of Galectin Therapeutics from a “buy” rating to a “sell” rating in a research report on Friday, May 20th. Finally, Roth Capital assumed coverage on shares of Galectin Therapeutics in a research report on Friday, July 1st. They issued a “buy” rating on the stock.

The firm’s market cap is $57.97 million. The stock has a 50-day moving average of $1.71 and a 200 day moving average of $1.47.

Galectin Therapeutics (NASDAQ:GALT) last announced its quarterly earnings results on Tuesday, August 9th. The company reported ($0.20) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.04. On average, analysts anticipate that Galectin Therapeutics Inc. will post ($0.89) earnings per share for the current fiscal year.

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.